Akeso Inc. has announced the initiation of a Phase III clinical trial involving ivonescimab, a PD-1/VEGF bispecific antibody, in combination with docetaxel for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that has progressed following PD-1/L1 inhibitors and platinum-based chemotherapy. This pivotal study, AK112-305/HARMONi-8A, recently dosed its first patient. Ivonescimab is notable for being the only bispecific immunotherapy antibody currently in Phase III registration trials for immunotherapy-resistant lung cancer. The trial aims to provide a novel treatment option for patients with IO-resistant NSCLC, leveraging the synergistic effects of targeting both PD-1 and VEGF pathways to reactivate anti-tumor immune responses. The results of this ongoing study have not yet been presented.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.